Biosimilar Riabni Gets FDA Approval
The biosimilar has been approved for the treatment of Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis.
Lymphoma
Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Intensive Chemotherapy Tolerable, Efficacious in HIV-Associated Burkitt Lymphoma
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Durable Responses Seen With Odronextamab in Refractory B-Cell NHLs
Encouraging antitumor activity and durable responses were reported with odronextamab among patients with highly refractory B-cell NHLs.
Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL
The bispecific CAR-T therapy targets CD20 and CD19.
Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Duvelisib Had Consistent Response Rates in R/R Peripheral T-Cell Lymphoma
Response appears to be consistent across histological subtypes.
Partial Response or Better Associated With Prolonged PFS With Ibrutinib in WM
Response depth appeared to be predictive of PFS in WM patients treated with ibrutinib.
Quality of Life Increased Among Survivors of Aggressive Lymphoma, and Was Sustained Long-Term
Using the FACT-G questionnaire, researchers measured the quality of life for survivors of aggressive lymphomas at diagnosis and at various time points up to 9 years postdiagnosis.
-
Loading...
-
Loading...
